Company ProfilePremium

Ajanta Pharma Limited

Company Profile Analysis

Tickers: AJANTPHARM.NS, 532331.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ajanta Pharma Limited - Company showcase

Year Founded & Workforce

1973

Ajanta Pharma Limited logo

Ajanta Pharma Limited Employee Contacts

31 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Ajanta Pharma Limited Overview

Ajanta Pharma is a Mumbai-headquartered, promoter-controlled specialty pharmaceutical formulation company whose economic engine is branded generics sold through its own field forces in India, Asia and Francophone/Anglophone Africa, complemented by a fast-scaling US generics business and a residual African institutional (antimalarial tender) franchise. It is distinctive among Indian mid-caps for three reasons: a portfolio built around first-to-market and niche molecules in cardiology, ophthalmology, dermatology and pain; very high gross margins (78.3% in FY2026) achieved through fully integrated, captive manufacturing at seven Indian plants; and a capital-light, cash-returning posture — negligible debt, a 33% return on capital employed in FY2026, and regular dividends and tender-offer buybacks. FY2026 was a milestone year in which revenue crossed INR 5,000 crore for the first time (INR 5,453 crore, +17%), driven by a 49% surge in US generics. The investment debate now centres on sustainability of US growth, Asia volatility and premium valuation.


Company's own description

In its FY2026 results communication, Ajanta describes itself as a specialty pharmaceutical formulation company with a major focus on branded generic business across India, Asia and Africa, complemented by a generics business in the United States and an institution business in Africa, with manufacturing facilities located in India. Management's stated growth model (Managing Director Yogesh Agrawal, Business Standard, December 2025) rests on new product launches, market-share gains in existing products, expansion into new countries and therapies, expense optimisation and digitalisation — a framework restated in the Q1 FY2027 results release.

Independent characterisation

Ajanta is best understood as a portfolio of four distinct businesses sharing one manufacturing and R&D platform:

  1. India branded generics (≈30% of FY2026 revenue). A specialty-led domestic franchise in which cardiology alone contributed 36% of India branded revenue in FY2026 (Q4 FY2026 call). Ajanta's operating model is to be first or early to launch novel combinations and new molecules in under-penetrated specialty niches, which historically gave it leadership positions in ophthalmology and dermatology sub-categories. Per IQVIA MAT March 2026, India branded performance exceeded Indian Pharmaceutical Market (IPM) growth by 33% (company press release, 5 May 2026). The India line also includes a small trade generics business (INR 188 crore in FY2026 vs INR 179 crore in FY2025).

  2. Emerging-market branded generics — Asia and Africa (≈37% combined). Ajanta operates its own sales teams in roughly 30 countries across South-East Asia (notably the Philippines), South Asia, the Middle East, Central Asia and Francophone/Anglophone Africa. Management restricts itself to 8–12 focus markets in each region rather than spreading thinly (Business Standard, December 2025). PL Capital estimates the branded generics business carries roughly a 30% operating margin.

  3. US generics (≈29%). A portfolio of oral solid generics manufactured at USFDA-inspected Indian sites, sold through Ajanta Pharma USA Inc. The business is deliberately niche: management states that nearly 40% of its US portfolio holds a 30% or higher market share (Business Standard, December 2025). Revenue grew 49% in FY2026 to INR 1,557 crore and 57% in Q1 FY2027 (to INR 487 crore; USD 51 million).

  4. Africa institution (≈3%). Tender-based supply of antimalarials and other products to global health procurement agencies; Ajanta was the first generic company worldwide to obtain WHO Geneva prequalification for an anti-malarial (company history). This business has shrunk structurally and is now a swing contributor (INR 160 crore in FY2026).

Business model and revenue model

DimensionCharacterisation
Revenue model mix~100% product sales (finished dosage formulations). No material service, subscription or licensing income identified. In-licensing (Biocon semaglutide) adds a distribution/commercialisation model from late 2026/2027
Branded vs generic mixBranded generics ~66–70% of revenue (66% in Q1 FY2027; ~71% per ICICI Direct FY2026); US generics ~29–30%; institutional ~3%
Value chain positionIntegrated: R&D (formulation development, bioequivalence, regulatory filings) → captive manufacturing (7 Indian plants; limited API for captive use) → own-field-force marketing in branded markets → wholesale/channel distribution in the US
Customer typesPrescribing physicians (specialists: cardiologists, ophthalmologists, dermatologists, physicians) influence demand; paying customers are distributors, stockists, pharmacies; in the US, wholesalers, retail pharmacy chains and group purchasing organisations; in Africa institution, donor-funded procurement agencies
End-marketsIndian domestic pharmaceutical market; emerging-market branded generics (Asia, Middle East, Central Asia, Africa); US generic prescription drugs; donor-funded antimalarial procurement

Strategy

Stated strategy themes (FY2026 annual report / investor communications)

Management's strategy is consistently framed around (i) new product launches, especially first-to-market products in specialty therapies; (ii) market-share gains in existing brands; (iii) expansion into new countries and therapies (recent entries into nephrology and gynaecology in India; new countries in Asia/Africa); (iv) expense optimisation; and (v) digitalisation across operations. The FY2026 Annual Report reiterates principles of quality without compromise, growth with margin discipline and value creation with integrity.

Strategic initiatives — last 24 months

DateInitiativeDetail / target
Mar 2025Pithampur liquid formulation facilityCapacity addition to meet emerging-market demand; existing capacity at 175% utilisation
FY2025–FY2026Field-force expansionTwo years of sales-team expansion in India (200 MRs added in specialty segments; 12 launches cited by PL Capital); productivity now improving
FY2025–FY2026Geographic expansion in Asia/AfricaBoard-level decision to enhance presence across select Asian and African geographies
Dec 2025Inorganic growth war chestINR 1,000 crore+ earmarked for brand/portfolio acquisitions (pain, dermatology, nephrology, gynaecology), not manufacturing assets
Dec 2025Semaglutide in-licensing (Biocon)26 countries; launch late 2026/early 2027
Jan 2026Ajanta Pharma Ireland LtdNew wholly owned subsidiary
FY2026–FY2027Semaglutide filings outside IndiaFiling programme commencing (ICICI Direct)
2023–ongoingESG data platformCredible Innovations partnership for AI-based ESG accounting and reporting
OngoingCapital returnDividend payouts (76% PAT payout in FY2025); periodic tender-offer buybacks

Management guidance

ItemGuidanceDate / source
FY2027 revenue growthHigh-teen growth (16–18%)Q4 FY2026 call, May 2026
FY2027 EBITDA margin~27% (range 26–28%)Q4 FY2026 call; maintained in July 2026
Rest-of-FY2027 growth (post Q1)Mid-single to upper-mid-single digit growth for the remaining quarters, citing US price erosion, new competition and a thin launch pipelineQ1 FY2027 call as reported by Equirus, July 2026
AsiaRecovery; high double-digit growth expected over time; Q1 deferred sales to be recognised in Q2Q4 FY2026 / Q1 FY2027 calls
Africa brandedHigh double-digit growthQ4 FY2026 call
US launchesNone in Q2 FY2027; most approvals expected in Q4 FY2027Q1 FY2027 call

Products & Services

Disclosure limitation: Ajanta does not publish a brand-level revenue catalog in its results materials, and brand-by-brand sales are sourced in India from proprietary IQVIA data. The catalog below therefore lists therapy franchises and disclosed launches; individual brand revenue, pricing and launch years are not publicly disclosed unless stated.

India branded generics

FranchiseDescription & positioningTarget prescriberDisclosed facts
Cardiology (cardio-metabolic)Largest India franchise; anti-hypertensives, lipid-lowering, anti-platelet and fixed-dose combinations; focus on new combinationsCardiologists, consulting physicians36% of India branded revenue in FY2026 (Q4 FY2026 call). Growth in the cardiac division has at times trailed IPM growth (Tickertape summary of FY2026 commentary). Company was directed by Indian regulator's expert committee to revise the bioequivalence protocol for a cilnidipine + metoprolol fixed-dose combination (Medical Dialogues, 2026) — evidence of continued cardiac FDC development
OphthalmologySpecialty eye-care portfolio (anti-allergics, anti-infectives, anti-glaucoma, dry-eye) where Ajanta holds leadership positions in several sub-segmentsOphthalmologistsLeadership described in company history; brand-level data not publicly disclosed
DermatologyTopicals and orals in acne, fungal infections, pigmentation and dermatitisDermatologistsIdentified by management as an area for bolt-on acquisitions (December 2025)
Pain managementAnalgesics, musculoskeletal and anti-inflammatory productsOrthopaedics, physiciansIdentified as an M&A gap-filling area (December 2025)
Nephrology (new)Recent entryNephrologistsEntered recently; management sees "meaningful scope" (Business Standard, December 2025)
Gynaecology (new)Recent entryGynaecologistsEntered recently (December 2025)
Trade genericsUnbranded/low-promotion generics sold through trade channelsPharmacies / tradeINR 188 crore in FY2026 vs INR 179 crore in FY2025; INR 49 crore in Q4 of both years

Launch cadence: 26 new products launched in India in FY2026, including five first-time-in-India launches (ICICI Direct, Q4 FY2026); eight new products launched in Q1 FY2027 (Equirus).

Asia branded generics

Portfolio spans cardiology, anti-diabetics, antibiotics, gastro, dermatology, ophthalmology and pain, increasingly tilted to chronic therapies. A consensus narrative cites ~25 new chronic-therapy launches planned to support FY2026+ growth (Simply Wall St analyst narrative, December 2024). Key markets include the Philippines (own subsidiary), Sri Lanka, Myanmar, Cambodia, Middle East (GCC) and Central Asia (exact market list not disclosed in the sources reviewed). FY2026 revenue: INR 1,175 crore (–1%), hurt by logistics and geopolitical disruptions (Q4 FY2026 call).

Africa branded generics

Strong presence in Francophone West and Central Africa and selected East African markets; portfolio emphasises anti-infectives, antimalarials (branded), cardio-metabolic and pain, with liquid oral formulations important (driver of the Pithampur liquids expansion). Eight new products introduced in FY2026 (one in Q4). FY2026 revenue: INR 861 crore (+15%); Q4 FY2026 +37%; Q1 FY2027 +~29%.

US generics

ItemDetail
Portfolio typeOral solids (tablets, capsules, extended-release); niche, limited-competition molecules
Named productsTopiramate Extended-Release Capsules (final USFDA approval, 2023); individual product revenues not disclosed
Pipeline19 ANDAs awaiting USFDA approval at end-FY2026 (press release, 5 May 2026)
Market share profile~40% of portfolio holds ≥30% market share (management, December 2025)
RevenueINR 1,557 crore FY2026 (+49%); USD 51 million in Q1 FY2027 (+30% in USD terms)
Near-term launch outlookNo new US launches expected in Q2 FY2027; most potential approvals pushed to Q4 FY2027 (Equirus, July 2026)

Africa institution

Antimalarial artemisinin-combination therapies supplied under donor-funded tenders (Global Fund-type procurement). Revenue INR 160 crore in FY2026 (+9%); Q4 FY2026 +71% on improved second-half order flow.

In-licensed: semaglutide (GLP-1 receptor agonist)

ItemDetail
CounterpartyBiocon Ltd (manufacturer and supplier)
SignedAnnounced 24 December 2025
Territory26 countries in Africa, the Middle East and Central Asia: exclusive in 23, semi-exclusive in 3
IndicationGlycaemic control in adults with type 2 diabetes
Patent contextProduct patent expires in most territories in March 2026
Expected launchAfter approvals anticipated late 2026 to early 2027
Sell-side estimatePL Capital estimates ~INR 200 crore of FY2028E sales at healthy margins (estimate, not company guidance)
Further filingsCompany to begin filing semaglutide outside India (ICICI Direct, Q4 FY2026 note)

Financial Narrative

Income statement (consolidated)

Sources: StockAnalysis (consolidated, INR millions converted to crore) for revenue, gross profit, operating income, net income, DPS, finance cost; Ajanta press release/Directors' Report FY2026 for revenue, PAT and EBITDA (FY2026 EBITDA INR 1,395 crore, +11% YoY; FY2025 EBITDA derived from the 11% growth figure); Craytheon for PBT; Motilal Oswal/askfuzz for EPS. Discrepancy note: Craytheon reports FY2025 gross profit of INR 3,577 crore vs StockAnalysis INR 3,505 crore (different cost-of-goods classification).

Margins and growth

Revenue CAGR FY2022–FY2026 (derived): ~13.0%. PAT CAGR FY2022–FY2026 (derived): ~10.3%. Company states a 3-year revenue and PAT CAGR of ~14% (FY2023–FY2026).

Commentary. The five-year record has three phases. FY2022–FY2023 saw margin compression: gross margin fell ~320 bps to 70.3% and EBIT margin dropped to 18.2% in FY2023 as input-cost inflation, freight disruption and the decline of the institutional business bit, driving the only PAT decline in the series (–17.5%). FY2024 was the inflection year: gross margin recovered to 73.4%, EBIT margin rebuilt to 24.8% and PAT rose 38.8% on price, mix and cost normalisation. FY2025–FY2026 have been about scaling: gross margin expanded a further ~490 bps to 78.3%, powered by branded mix and high-share US products, but the gain was reinvested in field-force expansion (employee cost +21.8% YoY in Q4 FY2026) and other expenses (+42.8% YoY in Q4 FY2026), so EBITDA margin actually slipped to ~26% in FY2026 from ~27% in FY2025. FY2026 operating leverage was therefore weaker than the headline 17% revenue growth suggests; PAT grew 14.7%, also helped by lower finance cost.

Quarterly trajectory FY2026–Q1 FY2027

Notes: Q2 and Q3 FY2026 revenue and Q2 FY2026 PAT are derived (Q3 revenue from Q4's reported +3.4% QoQ; Q2 as the residual of FY2026; Q2 PAT from 9M FY2026 PAT of INR 789 crore). Q1 FY2027 EBITDA is adjusted, excluding forex loss (company), equivalent to a ~28% margin; gross margin was 80% (+100 bps QoQ). Q3 FY2026 EBITDA margin was 27.8% (IIFL).

Balance sheet

Sources: Craytheon (FY2026 total assets, net worth, current ratio, D/E 0.06, debt +448.7% YoY). FY2025 debt derived from the reported 448.7% increase. Short/long-term debt split and net debt are not publicly disclosed in the sources reviewed. The FY2026 debt increase most plausibly reflects short-term working-capital borrowing or lease liabilities — not confirmed.

Cash flow and shareholder returns

Sources: 5paisa citing company (FY2024 dividends INR 642 crore); Craytheon (FY2025/FY2026 dividends paid; FY2026 FCF INR 164 crore); FY2025 Directors' Report (buyback INR 285 crore paid to shareholders + INR 65 crore tax, executed in Q1 FY2025). FY2025 payout: management cited a 76% PAT payout in FY2025 (Quartr summary).

Return and efficiency ratios

ROA (derived, FY2026): ~17.2% (PAT / year-end total assets). ROIC, net debt/EBITDA and the cash conversion cycle are not publicly disclosed in the sources reviewed; net debt/EBITDA is almost certainly negative (net cash). Craytheon reports interest coverage of 75.8x for FY2026 on a different definition.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (INR Cr)FY2025FY2026

India branded generics (incl. trade generics)

1,4521,654

Asia branded generics

1,1911,175

Africa branded generics

750861

Sub-total branded generics

3,3933,690

US generics

1,0471,557

Africa institution

147160

Other operating revenue (derived residual)

6146

Total revenue from operations

4,6485,453

Business line — YoY growth (%)

Business line — YoY growth (%)FY2025FY2026

India branded generics

—14

Asia branded generics

—-1

Africa branded generics

—15

US generics

—49

Africa institution

—9

Total revenue

1017

Business line — % of total revenue (derived)

Business line — % of total revenue (derived)FY2025FY2026

India branded generics

31.230.3

Asia branded generics

25.621.5

Africa branded generics

16.115.8

US generics

22.528.6

Africa institution

3.22.9

Business Lines (Quarterly)

Business line (INR Cr)Q4 FY2025Q4 FY2026Q4 growth %Q1 FY2027Q1 growth %

India branded

3694049

~510

24

Asia branded

303274-10

~260

-16

Africa branded

13318237

not separately verified

~29

Total branded generics

80585971,05913

US generics

3255055648757

Africa institution

284871

not separately verified

—

Group Entities

EntityJurisdictionFunction

Ajanta Pharma Limited

India

Parent; R&D, manufacturing, India and export sales

Ajanta Pharma USA Inc.

United States

US generics marketing and distribution

Ajanta Pharma Philippines Inc.

Philippines

Branded generics marketing in the Philippines

Ajanta Pharma (Mauritius) Ltd

Mauritius

Holding / export hub; historically associated with a WHO-GMP manufacturing site

Ajanta Pharma Ireland Ltd

Ireland

Incorporated January 2026; purpose not publicly detailed (likely European regulatory/market-access vehicle — analyst inference)

Other overseas marketing subsidiaries

Various (Asia/Africa)

Not individually verified in sources reviewed

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

3,3413,7434,2094,6485,453

Total income incl. other income (INR Cr)

3,4573,8414,2934,7435,625

Gross profit (INR Cr)

2,4572,6323,0883,5054,269

Operating income / EBIT (INR Cr)

8086801,0461,1291,325

EBITDA company-reported (INR Cr)

———1,2571,395

Profit before tax (INR Cr)

———1,1891,378

Net income / PAT (INR Cr)

7135888169201,056

EPS basic (INR)

———73.5684.53

Dividend per share bonus-adjusted (INR)

6.337362828

Finance cost (INR Cr)

10.25.87.220.716.1

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Revenue growth

15.612.012.410.417.3

Gross margin

73.570.373.475.478.3

Operating (EBIT) margin

24.218.224.824.324.3

EBITDA margin company-reported

———27.025.6

Net margin

21.315.719.419.819.4

Net income growth

9.0-17.538.812.814.7

Income Statement and Per-Share Data (Quarterly)

MetricQ1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027

Revenue (INR Cr)

1,3031,3531,3751,4221,626

PAT (INR Cr)

255260274267334

EBITDA (INR Cr)

———333454

EPS basic (INR)

20.44——21.3526.75

Balance Sheet and Financial Ratios (x)

MetricFY2025FY2026

Total assets (INR Cr)

—6,155

Shareholders' equity / net worth (INR Cr)

—4,527

Total debt (INR Cr, derived from D/E 0.06)

~50

~272

Current ratio (x)

—2.64

Dividends & Capital Returns

Metric (INR Cr)FY2024FY2025FY2026

Dividends paid

642349350

Buyback outlay incl. buyback tax

—3500

Free cash flow

——164

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

————23.3

Return on net worth company-reported (%)

————25

ROCE company-reported (%)

————33

Interest coverage EBIT/finance cost (x, derived)

791171455582

Debt/equity (x)

————0.06

Asset turnover revenue/total assets (x, derived)

————0.89

Revenue by Region

Region (INR Cr)FY2025FY2026

India

1,4521,654

Asia ex-India

1,1911,175

Africa (branded + institution)

8971,021

United States

1,0471,557

Region growth (%)

Region growth (%)FY2026

India

13.9

Asia ex-India

-1.3

Africa (branded + institution)

13.8

United States

48.7

Valuation Snapshot

MetricValueAs-of / source

Latest price

INR 3,399.40

12 Oct 2026 (IIFL)

52-week range

INR 2,329.90 – 3,796.95

Aug 2026 (Anand Rathi / IIFL)

6-month return

~+18.8%

Sep 2026 (Anand Rathi)

1-year return

~+35% to +38%

Sep 2026 (Kotak Neo / Anand Rathi)

3-year return

~+105% to +110%

Aug–Sep 2026 (Anand Rathi)

5-year return

~+139.5%

as of 2 Apr 2026 (Equentis) — not refreshed

Beta

~0.7

Equentis

Valuation Multiples

MultipleAjantaBasis

P/E (trailing)

37.4x

TTM EPS ~INR 90.84 (FY2026 84.53 + Q1 FY2027 26.75 – Q1 FY2026 20.44)

P/E (FY2026)

40.2x

FY2026 EPS 84.53

P/B

~9.4x

FY2026 net worth INR 4,527 crore

EV/Sales (FY2026)

~7.8x

Market-cap basis; net cash not deducted

EV/EBITDA (FY2026)

~30x

Market-cap basis; FY2026 EBITDA INR 1,395 crore

Dividend yield

~0.8–0.9%

INR 28 FY2026 / INR 32 FY2027 interim

Analyst Ratings & Targets

BrokerDateRatingTarget price (INR)

ICICI Securities

31 Jul 2026

Hold (downgrade)

3,260

Equirus Securities

31 Jul 2026

Reduce

—

Motilal Oswal

Jul 2026

Buy (reported)

4,000 (reported)

PL Capital

Dec 2025

Buy

3,200

Consensus (Trendlyne)

Aug 2026

Buy

~3,761

“—” = not publicly disclosed.

Per-Share Data and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share bonus-adjusted (INR)

6.337362828

Dividends paid (INR Cr)

——642349350

Analyst Conclusions

Guidance and expectations

Management guided in May 2026 to high-teen (16–18%) revenue growth and ~27% EBITDA margin for FY2027, then struck a more cautious tone in July 2026, guiding to mid- to upper-mid-single-digit growth for the remainder of the year. Sell-side expectations reported in press imply low- to mid-teens EPS growth into FY2028 (ICICI Securities values the stock at 28x FY2028E EPS).

Bull case

  1. Margin engine intact: gross margin at 80% in Q1 FY2027 and ROCE of 33% indicate a franchise that can absorb investment and still compound earnings in the mid-teens.

  2. Multiple growth options: semaglutide in 26 EMs (~INR 200 crore FY2028E per PL Capital), Africa high double-digit growth, Asia recovery from a depressed base, and INR 1,000 crore of firepower for India brand acquisitions.

  3. Regulatory de-risking: Paithan VAI removes the main overhang on the US franchise; 19 pending ANDAs support US growth from Q4 FY2027.

Bear case

  1. US normalisation: management itself flags price erosion, new competition and no Q2 launches; after +49% and +57% growth, a reversal in a 29%-of-revenue business would hit earnings disproportionately.

  2. Weak operating leverage and cash conversion: EBITDA margin fell to ~26% in FY2026 despite +17% revenue; FCF of INR 164 crore in FY2026 is low relative to INR 1,056 crore PAT.

  3. Valuation and supply overhang: ~37x trailing earnings and ~9.4x book, alongside promoter selling (2.76% in June 2026) and rising pledges, limit upside; two brokers rate the stock Hold/Reduce.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Q2 FY2027 results: Asia catch-up of deferred Q1 sales; US sequential trendLate Oct / early Nov 2026
Semaglutide approvals and first launches in licensed territoriesLate 2026 – early 2027
First acquisition under INR 1,000 crore programmeFY2027 (unconfirmed)
US ANDA approvals (most pushed to Q4 FY2027)Jan–Mar 2027
Commissioning of Pithampur liquid facility—
Reconciliation of FY2027 growth guidanceQ2/Q3 FY2027 calls
Further promoter sales or pledge changesOngoing
Next USFDA inspections (Dahej / other sites)Unscheduled
FY2027 dividend / potential buybackQ3–Q4 FY2027 / May 2027

Analyst verdict

Ajanta Pharma enters the second half of FY2027 as one of the highest-quality mid-cap franchises in Indian pharmaceuticals, but one whose share price already discounts much of that quality. The fundamental record is genuinely strong: revenue has compounded at ~13% over FY2022–FY2026 to INR 5,453 crore, gross margin has expanded by roughly 800 bps since FY2023 to 78%, ROCE stands at 33%, the balance sheet is essentially ungeared, and the July 2026 quarter delivered 25% revenue growth and 31% PAT growth with an 80% gross margin. The Paithan VAI outcome and the Biocon semaglutide licence materially improve the medium-term risk-reward, and the INR 1,000 crore acquisition allocation gives management a lever to accelerate the India business, which is already outgrowing the market by a third.

Against this, three issues temper conviction. First, the growth mix has become more dependent on the US, the most cyclical and deflationary of Ajanta's markets; management's own July commentary — mid-single-digit growth for the rest of the year and no near-term launches — signals that FY2026–Q1 FY2027 US growth was a peak, not a run-rate. Second, operating leverage and cash conversion in FY2026 were weaker than headline growth implied, as field-force and other expenses outpaced revenue and working capital absorbed cash. Third, the stock trades at ~37x trailing earnings and ~9.4x book while promoters have been net sellers and pledges have risen.

Net, Ajanta is a hold-quality compounder at current levels: the business merits a premium multiple, but upside from here depends on evidence that Asia recovers in Q2, that semaglutide launches on schedule, and that capital is deployed in value-accretive acquisitions. Investors should treat the Q2 FY2027 print as the key arbiter of whether FY2027 full-year growth tracks the May "high-teens" guidance or the July caution.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleCategoryBoard tenure / key datesBackground (as disclosed)

Mannalal B. Agrawal

Chairman

Non-Executive, Non-Independent (promoter)

Long-standing (~46 years per Simply Wall St)

Co-founder; also director of Ajanta Pharma Philippines and Ajanta Pharma (Mauritius)

Madhusudan B. Agrawal

Executive Vice-Chairman

Executive (promoter)

Re-appointed for 5 years from 1 April 2025

Co-founder; director of Ajanta Pharma USA Inc.

Yogesh M. Agrawal

Managing Director

Executive (promoter)

Director since 29 April 2000; current term from 1 April 2023; born 14 January 1972 (age 54)

MBA; leads the global business

Rajesh M. Agrawal

Joint Managing Director

Executive (promoter)

Director since 30 April 2013; current term from 1 May 2023; born 31 March 1976 (age 50)

Leads operations/strategy; publicly articulated M&A plans (December 2025)

David Rasquinha

Lead Independent Director

Independent

——

Medha Joshi

Independent Director

Independent

—

Not detailed in sources reviewed

Simi Thapar

Independent Director

Independent

Appointed at the 2024 AGM

Not detailed in sources reviewed

Rajesh Shashikant Dalal

Independent Director

Independent

—

Not detailed in sources reviewed

Executive Leadership Team

NameTitle

Yogesh M. Agrawal

Managing Director

Rajesh M. Agrawal

Joint Managing Director

Arvind Agrawal

Chief Financial Officer

Gaurang Shah

Senior Vice President – Legal & Company Secretary

Directors' Remuneration

ExecutiveTotal remunerationSource / year

Yogesh M. Agrawal (MD)

INR 24.64 crore (INR 246.4 million); salary ~57.7% of total

Simply Wall St, FY2025 basis

Madhusudan B. Agrawal (Executive Vice-Chairman)

INR 4.84 crore

Simply Wall St, FY2025 basis

Mannalal B. Agrawal (Chairman)

INR 0.075 crore (sitting fees/commission)

Simply Wall St

Stock-based pay

Share-Based Incentive Plan 2019 (SBIP 2019): 25,325 options vested/issued in FY2025; 13,000 US-employee options converted to cash-settled SARs

FY2025 Directors' Report

Board & Management Changes

DateChange

2024 AGM

Induction of new independent directors including Simi Thapar; board committees reconstituted following retirement of earlier independent directors

1 April 2025

Madhusudan B. Agrawal re-appointed Executive Director & Vice-Chairman (5 years) — approved at AGM on 17 July 2025

FY2026

David Rasquinha continues as Lead Independent Director; a director retiring by rotation recommended for re-appointment at the 47th AGM (16 July 2026)

Shareholding Pattern

CategoryMar 2026 (%)Post 9 June 2026 / Jun 2026 (%)

Promoters & promoter group

66.2563.49

Mutual funds

15.22—

Foreign portfolio investors

8.26

~7.7

Other domestic institutions

3.14

~3.7

Retail & others

7.12

~7.0

Major Shareholders

HolderStake (%)TypeDate

Rajesh Agrawal Trust (Rajesh M. Agrawal, trustee)

14.47

Promoter

Mar 2026

Aayush Agrawal Trust

11.30

Promoter

Jun 2026

Ravi Agrawal Trust

10.24

Promoter

Jun 2026 (from 13.00%)

Gabs Investments Pvt Ltd

10.08

Promoter

Jun 2026

UTI Flexi Cap Fund

3.19

Mutual fund

Mar 2026

Kotak Mahindra Mutual Fund (block purchase)

≥1.68

Mutual fund

Jun 2026 (21.02 lakh shares bought)

Canara Robeco Mutual Fund (various schemes)

~1.5 (largest single scheme)

Mutual fund

Dec 2025

Aditya Birla Sun Life Mutual Fund (block purchase)

≥1.08

Mutual fund

Jun 2026 (13.47 lakh shares bought)

Competitive Landscape

Competitors by Segment

Business linePrincipal competitors

India branded — cardiology/cardio-metabolic

Sun Pharma, Torrent Pharma, Lupin, Mankind Pharma, Eris Lifesciences, Micro Labs, Alkem

India branded — ophthalmology

Sun Pharma (ophthalmic division), FDC Ltd, Entod Pharmaceuticals, Cipla, Alcon/Novartis (innovator)

India branded — dermatology

Glenmark, Sun Pharma, Mankind, Alkem, Abbott India

India branded — pain

Alkem, Ipca Laboratories, Mankind, Abbott India

Asia branded generics

Unilab (Philippines, local leader), Getz Pharma, Hetero, Sun Pharma, Torrent, Dr. Reddy's, multinationals

Africa branded generics

Ipca Laboratories, Cipla, Strides Pharma, Bliss GVS Pharma, Sanofi, Aspen, local manufacturers

US generics

Zydus Lifesciences, Lupin, Alembic Pharma, Aurobindo, Torrent, Unichem, Glenmark, Teva

Africa institution (antimalarials)

Ipca Laboratories, Macleods, Strides, Guilin Pharma, Novartis (innovator)

Key Competitors

CompanyFY2026 revenue (INR Cr)Notes

Ajanta Pharma

5,453

Revenue growth 17%; gross margin 78%; EBITDA margin 26%; R&D ~5% of revenue

Ipca Laboratories

9,646

Closest overlap in Africa institution, pain and EM branded generics

Alembic Pharmaceuticals

7,345

Overlap in US generics and India specialty

Sun Pharmaceutical Industries

58,462

Category leader in India specialty and EMs (Craytheon also reports INR 60,434 crore — source discrepancy)

Company Snapshot

$629.7M

Revenue

1973

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Exceptional gross margin: 78.3% in FY2026, up from 70.3% in FY2023 (StockAnalysis), and 80% in Q1 FY2027.
  • High returns: ROCE 33% and RoNW 25% in FY2026 (company).
  • US momentum: US generics revenue +49% in FY2026 to INR 1,557 crore; +57% in Q1 FY2027.
  • India outperformance: India branded growth exceeded IPM by 33% (IQVIA MAT March 2026); 26 launches in FY2026.
  • Balance sheet: debt/equity 0.06 and interest coverage ~76–82x in FY2026; capacity to fund an INR 1,000 crore+ acquisition programme internally.
  • Regulatory compliance: Paithan April 2026 inspection closed as VAI (EIR, July 2026).
  • Shareholder returns: FY2025 PAT payout ~76%; INR 350 crore buyback in FY2025; INR 32/share interim dividend in July 2026.

Weaknesses

  • Asia stagnation: Asia revenue –1% in FY2026 and –16% in Q1 FY2027.
  • Operating leverage slippage: EBITDA margin ~26% in FY2026 vs ~27% in FY2025 despite +17% revenue; Q4 FY2026 other expenses +42.8% YoY.
  • Cash conversion: FY2026 operating cash flow trailed net income; FCF only INR 164 crore (Craytheon).
  • Concentration in cardiology: 36% of India branded revenue, a therapy where growth has at times lagged IPM.
  • Thin near-term US launch pipeline: no launches in Q2 FY2027; approvals pushed to Q4 FY2027.
  • Governance concentration: four of eight directors are promoter-family members; ~13.9% of equity encumbered (June 2026).

Opportunities

  • Semaglutide: 26-country rights; PL Capital estimates ~INR 200 crore FY2028E sales.
  • M&A: INR 1,000 crore+ for brand acquisitions in pain, dermatology, nephrology and gynaecology.
  • New Indian therapies: recent entry into nephrology and gynaecology.
  • Africa: management expects high double-digit Africa branded growth; Q4 FY2026 +37%, Q1 FY2027 ~+29%.
  • Liquids capacity: Pithampur liquid facility to relieve 175% utilisation constraint.
  • US pipeline: 19 ANDAs pending approval.

Threats

  • US price erosion and competition: explicitly cited by management in July 2026 as reasons for slower growth.
  • Geopolitics/logistics: Middle East disruption deferred Asia shipments (Q1 FY2027).
  • USFDA risk: five observations at Paithan in April 2026 show residual compliance risk.
  • Promoter selling: two secondary sales (4.3% in Dec 2022; 2.76% in Jun 2026) and new pledges may weigh on sentiment.
  • Valuation: stock at ~37x trailing EPS and ~9.5x book; ICICI Securities and Equirus cite stretched valuations.
  • India regulation: price controls and FDC regulatory scrutiny (e.g., required revision of BE protocol for cilnidipine/metoprolol FDC).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 Apr 2025Q4 FY2025 results: PAT +11% to INR 225 crore; EBITDA margin 25%Closed FY2025 with revenue INR 4,648 crore (+10%)
Q1 FY202610 new branded generic launches in the quarterPipeline execution
17 Jul 202546th AGM approves re-appointment of Executive Vice-ChairmanGovernance continuity
Jul/Aug 2025Q1 FY2026 results: revenue INR 1,303 crore (+14%); PAT INR 255 crore (+4%)Expense growth outpaced revenue (field-force investment)
Oct 2025Q2 FY2026 results with interim dividend (INR 28/share); shares +3%FY2026 dividend declared
Oct–Nov 2025PL Capital initiates/retains Buy; Nuvama highlights growth amid US challengesSell-side support
11 Dec 2025INR 1,000 crore+ M&A allocation disclosedShift toward inorganic India growth
24 Dec 2025Semaglutide in-licensing with Biocon; shares rise ~5% to 5-month highNew growth vector for FY2028+
26 Dec 2025PL Capital retains Buy, TP INR 3,200; sees ~INR 200 crore FY2028E semaglutide salesQuantification of deal
13 Jan 2026Ajanta Pharma Ireland Ltd incorporatedStructural expansion
30 Jan 2026Q3 FY2026: revenue +20%, PAT +17.6% to INR 274 crore; EBITDA margin 27.8%Acceleration driven by US and India
6 Apr 2026Q4 FY2026 depository compliance certificate filedRoutine
13–21 Apr 2026USFDA inspection at Paithan; Form 483 with five observationsRegulatory risk event
22 Apr 2026Exchange disclosure of Paithan 483Market informed
5 May 2026FY2026 results: revenue INR 5,453 crore (+17%), PAT INR 1,056 crore (+15%), EBITDA INR 1,395 crore (26% margin); US +49%; ROCE 33%Record year; beats estimates (Motilal Oswal: 10%/17%/21% beat on revenue/EBITDA/PAT for Q4)
May 2026FY2027 guidance: high-teen growth, ~27% EBITDA marginBullish guidance
2 Jun 2026Gabs Investments (promoter) pledges 2.22% to secure a loanPromoter encumbrance rises to ~13.9%
9 Jun 2026Ravi Agrawal Trust sells 2.76% for INR 1,024 crore; Kotak MF and ABSL MF buyPromoter stake falls to 63.49%; free float improves
15 Jun 202647th AGM notice; record date 12 June for report dispatchRoutine
19 Jun 2026Ravi Agrawal releases excess pledge on 23.26 lakh sharesPartially offsets pledge concern
2 Jul 2026USFDA EIR for Paithan; VAI classificationRemoves key regulatory overhang
16 Jul 202647th AGM heldRoutine
30 Jul 2026Q1 FY2027: revenue INR 1,626 crore (+25%), PAT INR 334 crore (+31%), US +57%, India +24%, Asia –16%; interim dividend INR 32 (record date 5 Aug 2026)Strong beat; cautious outlook for remainder of year
31 Jul 2026ICICI Securities downgrades to Hold (TP INR 3,260, 28x FY2028E EPS); Equirus retains Reduce; Motilal Oswal TP INR 4,000 (reported)Valuation debate intensifies
Aug 2026Stock reaches 52-week high of ~INR 3,797Market re-rating
16 Sep 2026Participation in Jefferies India Forum (New Delhi)Investor engagement
28 Sep 2026Participation in PL Capital Mid & Small Cap Conference (Mumbai)Investor engagement
Oct 2026 (expected)Q2 FY2027 results — date not confirmed as of 19 Oct 2026Key test of Asia recovery and US trajectory

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2025–FY2026): Total revenue from operations rose from INR 46,480 Mn in FY2025 to INR 54,530 Mn in FY2026.
Ajanta Pharma Limited — Revenue by Segment (FY2025–FY2026)
Series (INR Mn)FY2025FY2026
Total revenue from operations46,48054,530
India branded generics (incl. trade generics)14,52016,540
Asia branded generics11,91011,750
Africa branded generics7,5008,610
Sub-total branded generics33,93036,900
US generics10,47015,570
Africa institution1,4701,600
Other operating revenue ( residual)610460

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.